Check-Cap

Company Overview

Snapshot

Founded in January 2005 by Yoav Kimchy, Check-Cap operates with 11–50 employees. The company has raised a total of $134.22 million across 15 funding rounds. In September 2025, Check-Cap was acquired by MBody AI.

Business overview

Check-Cap is a clinical-stage medical diagnostics company focused on redefining colorectal cancer (CRC) screening. Its core product, C-Scan, is a patient-friendly, preparation-free screening test that uses an ultra-low dose X-ray capsule, an integrated positioning, control, and recording system, and proprietary software to generate a 3D map of the colon's inner lining. This non-invasive technology aims to increase screening adherence by detecting polyps before they develop into colorectal cancer. Check-Cap operates within the Health Tech & Life Sciences sector, specifically targeting digital healthcare and medical devices, and serves the healthcare market by providing solutions for patients and providers.

Strategic signal

In September 2025, Check-Cap entered into a definitive merger agreement with MBody AI, a move aimed at creating a combined entity focused on embodied AI for the autonomous workforce. This strategic shift indicates Check-Cap's pivot from its core medical diagnostics business towards a high-growth industry, leveraging its legacy assets while capitalizing on MBody AI's expertise. This signals a significant transformation in the company's strategic direction and market focus, moving into the broader AI market.

Company Intelligence Q&A

What was the most significant corporate event for Check-Cap in 2025?

In September 2025, Check-Cap and MBody AI announced a definitive merger agreement to form a combined company focused on embodied AI for the autonomous workforce. The combined entity will retain Check-Cap's legacy assets and be renamed MBody AI Ltd.

What legal challenge did Check-Cap face in June 2025?

In June 2025, Check-Cap publicly condemned MediPharm Labs Corp. and its Chairman, Chris Taves, for issuing false and defamatory statements. Check-Cap accused Taves of exploiting his position at BMO Capital Markets to manipulate its stock price and demanded a retraction and apology.

What was the outcome of the shareholder vote regarding the proposed merger with Keystone Dental in December 2023?

In December 2023, Check-Cap shareholders voted in favor of all director nominees proposed by Symetryx and rejected the proposed merger with Keystone Dental. Symetryx, a significant shareholder, advocated for a more suitable merger candidate.

What was the status of Check-Cap's U.S. pivotal study in March 2023?

In March 2023, Check-Cap announced that the efficacy results from its C-Scan calibration studies did not meet the internal goals required to proceed with the powered portion of the U.S. pivotal study. The company planned to conduct additional clinical data analysis and amend the study protocol.

What was the impact of the COVID-19 pandemic on Check-Cap's operations in April 2020?

In April 2020, Check-Cap provided an update on the impact of the COVID-19 pandemic, which led to the temporary suspension of clinical trials, implementation of cost reduction measures including a 15% salary reduction, and placing some operational employees on unpaid leave.